Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Journal of Gynecologic Oncology|November 25, 2022
Intraoperative frozen pathology exam of Common iliac lymph nodes and Para-Aortic lymphadenectomy on the prognosis and quality of life for patients with IB2-IIA2 Cervical Cancer: trial protocol for a randomized controlled trial (C-PACC trial)Xinyu Qu, Junjun Qiu, Lili Jiang, et al.Chinese Medical Journal|April 28, 2024
Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in ChinaDengfeng Wang, Xunwei Shi, Jiao Pei, et al.Journal of Ovarian Research|January 25, 2026
Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort studyMing Du, Peng Peng, Dongyan Cao, et al.Journal of Ovarian Research|January 11, 2021
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancerZhen Yuan, Ying Zhang, Dongyan Cao, et al.Oncogene|April 26, 2022
Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypesShan Zhu, Chunliu Zhang, Dongyan Cao, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 18, 2022
Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening: A multicenter randomized controlled trial in different resource settings in ChinaLe Dang, Linghua Kong, Yuqian Zhao, et al.JAMA Oncology|December 30, 2020
Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical TrialJunji Zhang, Yuqian Zhao, Yi Dai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II StudyLingfang Xia, Keqiang Zhang, Ying Tang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.Pageof 5